logo

Insmed Inc (INSM)



Trade INSM now with
  Date
  Headline
11/13/2020 8:05:29 AM Insmed Receives Priority Medicines Designation From EMA For Brensocatib In Patients With NCFBE
10/28/2020 7:44:59 AM Insmed Says European Commission Grants Marketing Authorization For ARIKAYCE® Liposomal 590 Mg Nebuliser Dispersion
10/2/2020 8:05:35 AM Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
9/4/2020 8:01:24 AM Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
8/6/2020 7:43:33 AM Insmed Q2 Net Loss $61.9 Mln Or $0.64/shr Vs. Net Loss $66.5 Mln Or $0.81/shr Last Year
7/24/2020 7:54:41 AM Insmed Receives Positive CHMP Opinion For ARIKAYCE Liposomal 590 Mg Nebuliser Dispersion
7/7/2020 8:06:35 AM Insmed : NTM Treatment Guidelines Recommend ARIKAYCE For Treatment Of Patients With Refractory MAC Lung Disease
6/24/2020 4:03:49 PM Insmed: Brensocatib Reduces Time To First Pulmonary Exacerbation And Reduces Rate Of Exacerbations Versus Placebo
6/8/2020 8:07:13 AM Insmed Gets FDA Breakthrough Therapy Designation For Brensocatib In Patients With Non-Cystic Fibrosis Bronchiectasis
5/20/2020 9:31:13 AM Insmed To Present New Data From Phase 2 WILLOW Study Of Brensocatib
5/5/2020 8:05:53 AM Insmed Prices Underwritten Public Offering Of 9.7 Mln Shares At $23.25/shr
4/30/2020 7:42:59 AM Insmed Q1 Net Loss $66.4 Mln Or $0.74/shr Vs. Net Loss $74.2 Mln Or $0.96/shr Last Year
2/25/2020 7:36:51 AM Insmed Q4 GAAP Net Loss $53.0 Mln Or $0.59/Shr Vs GAAP Net Loss $91.6 Mln Or $1.19/Shr Last Year